Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same author

Correction to: Romosozumab: A Review in Postmenopausal Osteoporosis.

Drugs & aging·2020
Same journal

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same journal

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Targeted oncology·2026
Same journal

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

Targeted oncology·2026
Same journal

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Targeted oncology·2026
Same journal

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026
Same journal

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Targeted oncology·2026
See all related articles

Related Experiment Video

Updated: Nov 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Lesley J Scott1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Targeted Oncology
|November 25, 2020
PubMed
Summary
This summary is machine-generated.

Darolutamide (Nubeqa™) significantly improved metastasis-free and overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC). This novel androgen receptor inhibitor demonstrated a favorable safety profile in the ARAMIS trial.

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.7K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.5K

Related Experiment Videos

Last Updated: Nov 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.7K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.5K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-metastatic castration-resistant prostate cancer (nmCRPC) requires effective treatment options.
  • Second-generation androgen receptor (AR) inhibitors play a crucial role in managing nmCRPC.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral darolutamide (Nubeqa™) in patients with nmCRPC.
  • To assess darolutamide's impact on metastasis-free survival (MFS) and overall survival (OS).

Main Methods:

  • Phase 3, multinational, randomized controlled trial (ARAMIS).
  • Comparison of darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT.
  • Extended follow-up for safety and survival outcomes.

Main Results:

  • Darolutamide significantly prolonged MFS and OS compared to placebo.
  • Darolutamide was generally well-tolerated with a low incidence of CNS-related adverse events.
  • Extended follow-up confirmed the efficacy and safety profile.

Conclusions:

  • Darolutamide plus ADT is an effective and safe treatment option for men with nmCRPC.
  • Darolutamide represents an important emerging therapy for high-risk nmCRPC patients.
  • Further real-world data will continue to define the long-term safety of darolutamide.